beispielsweise, weil du neulich gefragt hast: Was man im Netz so alles findet. 
Beim stöbern und lesen so nach und nach habe ich eine Deal-Ankündigung für wahrscheinlich Q3 entdeckt:
Genesis Research & Development
Stand 9.5.2008
Da steht so allerhand drin über eines ihrer focussierten Programme Zyrogen, der ja bekanntlich ein HuCAL-AK ist:
Auf Seite 5 für Zyrogen bei Osteoporosis steht unter anderem:
Current Status
Human antibodies produced
in vitro efficacy data
late pre clinc
Und auch: Phase 1 2009
Eine Zweite Indikation bei Lupus (Seite7) hat Klinikstart auf 2010.
Hier Ausüge aus dem Jahresbericht:
Zyrogen
Zyrogen is our name for FGFR5,
a fibroblast growth factor receptor
family member identified by Genesis
from our proprietary EST databases.
The fibroblast growth factor (FGF)
receptors play key roles in skeletal
development and this is most clearly
demonstrated in patients with
mutations in these receptors. Specific
mutations in FGFR1, 2 and 3 have
been associated with the Crouzon,
Apert, Pfeiffer, Jackson-Weiss and
Beare-Stevenson syndromes, human
diseases characterised by abnormal
bone development. Studies performed
at Genesis and other laboratories
show that the fifth member of the FGF
receptor family, Zyrogen, appears
to play an important role in bone
development and diseases where
bone loss is a feature.
FGFR5 is preferentially expressed in
developing musculoskeletal tissues
and is expressed by osteoblasts which
play a critical role in the development of
both the bone and the immune systems.
Osteoblasts lay down new bone and
regulate the action of osteoclasts
which resorb old bone. In addition,
osteoblasts are a critical component
of the bone marrow and influence the
development of B cells.
Our studies indicate that FGFR5
is a potential therapeutic target
in osteoporosis and autoimmune
disorders, as well as cancers which
are characterised by excess bone
resorption.
Genesis has worked with MorphoSys,
an international developer of therapeutic
human antibodies to select a panel of
fully human FGFR5 antibodies. These
will be tested for their ability to inhibit
disease progression in several models
of diseases including rheumatoid
arthritis and osteoporosis.
This work on FGFR5 antibodies has
led to a formal research collaboration
between Genesis and MorphoSys,
an agreement recognising both the
commercial potential and scientific
excellence of Genesis and its
Zyrogen programme together with the
therapeutic potential of the MorphoSys
fully human antibodies.
During 2007, Genesis filed patent
applications that will put us in a
strong position for protecting the new
antibodies. New experimental data
demonstrating the efficacy of these
antibodies will be added to this IP to
strengthen and ring-fence our claims.
We plan to complete the pre-clinical
development of a therapeutic antibody,
including toxicology studies and GMP
manufacture and to commence a
Phase I clinical trial. This trial could
commence in 2009.
We have previously reported our
intention to out-license the Zyrogen
project due to the significant technical
and financial inputs required for
the development of a commercial
therapeutic antibody. Our general
commercialisation strategy is to develop
projects through to Phase II clinical
trials and then out-license them to large
biotech or pharmaceutical companies
that have the necessary manufacturing
and marketing infrastructure and
experience to market a drug in all key
global markets. We will, however, also
consider earlier out-licensing provided
reasonable financial returns are still
achieved for Genesis shareholders, or if
the project requires technical expertise
that is outside our competencies. Outlicensing
provides a mechanism for
risk sharing, accessing technical and
marketing expertise and achievement
of early financial returns.
We have continued to update a number
of companies that have expressed
strong interest in the project and its
commercial development and believe
that there is a high likelihood of
achieving a license or collaboration
agreement during 2008-9.
.....
Share market Performance
The market capitalisation of Genesis
is currently $3.9 million and has
continued to be substantially below
the net assets which were $8.7 million
at 31 December 2007, and fails to
recognise the value of the intellectual
property held by Genesis which is being
used to develop commercial value in our
major projects.
This situation is common to many
biotech companies but can lead to
substantial re-rating as the company
achieves commercial success. Recently
a Japanese company licensed the world
wide rights (other than Asia) to its
antibody therapeutic which is in Phase I
studies to a major USA based biotech
for US$100 million upfront and further
potential payments of several hundred
million dollars, together with royalties.
This indicated the potential for Genesis
as it moves to get a Zyrogen antibody
into clinical development.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Bei 26 mio Aktien und Kurs von 0,13 NZE ist der Laden aktuell 3,4 mio NZE wert.
Was ist ein NZE in Euro?  Ich such das nachher noch.
Cashbestand am Jahresanfang war 5,8 mio. Am Jahresende soll er Planmäßig bei 3,1 mio NZE sein. Damit notiert die Firma kaum über Cashbestand, wahrscheinlich im Moment sogar deutlich unter cash!
Wie wäre es mit einer Übernahme anstatt Co-Entwickler?
Oder will Moroney das kleine Neuseeländische Biotec selbständig leben lassen mit MOR-Entwicklungsgeldern?
1 Neuseeländischer Dollar liegt bei 0,4812 Euro.
Wenn ich das richtig rechne, dann ist der Laden im Moment an der Börse mit 1,64 mio€ bewertet, was auch als cash vorhanden ist. Wobei der Kurs von 8 herkommt und nun auf 0,13 gefallen ist. 
Kann das mal jemand nachrechnen?
Da sollte man doch mit 2 bis 400% Aufschlag übernehmen können, wenn das Programm wirklich einen Wert hat?
xxxxxxxxxxxxxxxxxxxxx
Im Geschäftsbericht von Genesis kann man auch über die Potentiale von Osteoporosis nachlesen. 80 mio Patienten in den Schlüsselmärkten.
Naja, ein neuseeländisches Biotec und niemand interessiert es. |
Thread abonnieren
